Merlintrader Blog

AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.

Biotech Radar July 28, 2026: Kiniksa Rerates, Nautilus Pushes Voyager Shipments to Mid-2027 and Alkermes Expands Its Sleep Franchise — $KNSA $NAUT $ALKS

Biotech Radar July 28 2026 - $KNSA Kiniksa, $NAUT Nautilus, $ALKS Alkermes

Today’s Radar separates a genuine commercial-plus-clinical rerating at Kiniksa from a material commercialization-timeline reset at Nautilus Biotechnology and a strong but more complex post-acquisition quarter at Alkermes. NeoGenomics and Mirion remain on the closing-bell watchlist, with results scheduled after the market closes.

Golden Dome Enters the Procurement Era: 108 Tracking Satellites, the FY2027 Funding Fight and What It Means for $LHX $RKLB $LMT $NOC

Golden Dome

Golden Dome is no longer only a presidential vision or a broad market narrative. Congress has begun writing oversight into law, billions are moving through missile-warning and tracking awards, and the next political battle is already forming around FY2027 funding, space-based interceptors, acquisition authority and the true cost of defending the U.S. homeland.

Cannabis News Today: DEA Rescheduling, U.S. Hemp and $ACB $TLRY $CRON $CGC

Cannabis Today

A complete cannabis-sector update: the federal hearing is over, but a decision is not imminent; Congress is split between legalization and an attempt to block rescheduling; industry political donations are rising; and a parallel court fight could delay the process. Meanwhile, Aurora Cannabis, Tilray Brands, Cronos Group and Canopy Growth are looking for company-specific catalysts that do not depend entirely on Washington.

Betting on the FDA: How Kalshi’s Biotech Prediction Markets Work, and What They Mean for $XBI, $IBB and the Sector

Kalshi biotech prediction markets on FDA decisions and clinical trials, and what they mean for XBI and IBB

Kalshi launched a pilot program on July 16, 2026, enabling trading on clinical trial outcomes and FDA decisions linked to biotech firms. This new prediction market offers a public price reflecting the probability of drug approval, but raises ethical concerns and potential manipulation risks due to limited participant knowledge and liquidity challenges.